HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 02, February 2017 – War on CANCER       » Two Scientists Share China's Top Science Award       » China Donates Mobile Clinics to Kenya       » Cervical Cancer: A Preventable Disease       » One More Piece in the Puzzle of Liver Cancer Identified       » Smoking While Pregnant May Compromise Children's Kidney Function       » You Are What You Exhale      
BIOBOARD - US
Research Study on PAZ320 Initiated at University of Minnesota

Boston Therapeutics, Inc. a developer of drugs based on complex carbohydrate chemistry to treat diabetes, is sponsoring a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes.

The study is titled, "NMR studies of PAZ320 with sugar hydrolyzing enzymes" and will be conducted by Kevin H. Mayo, Ph.D., a professor in the Department of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota (UMN), Minneapolis. Dr. Mayo's lab at the UMN has been using NMR spectroscopy for many years to investigate interactions of various carbohydrates and proteins.

The study aims to provide molecular-level information on PAZ320 and its mechanism of action. Specifically, the study aims to better characterize PAZ320 galactomannan, and assess interactions of PAZ320 with various sugar-hydrolyzing enzymes, e.g., glucosidase and maltase. The study may also offer insight into allosteric properties of PAZ320 with enzymes, gauge the effect of PAZ320 on enzyme-mediated sugar hydrolysis, and compare PAZ320 with other diabetes drugs.

Dr. Mayo commented that "PAZ320 appears to be a promising compound in the treatment of diabetes and deserves closer evaluation by the scientific community. This Boston Therapeutics supported investigation is designed to assess biomolecular interactions between PAZ320 and various sugar hydrolyzing enzymes, and should contribute to understanding PAZ320's mechanism of action on the molecular level."

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "We are greatly encouraged by the results obtained to date regarding the ability of PAZ320 to reduce the elevation of post-meal blood glucose. We expect this new study at the University of Minnesota will deepen our understanding of this compound on a molecular level, and strengthen our knowledge of its potential as a drug for diabetes patients."

Source: Boston Therapeutics

Click here for the complete issue.

NEWS CRUNCH  
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
news MIT Hacking Medicine Robotics in Singapore!
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Traditional Chinese Medicines
April:
Diabetics Technology
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy